0001415889-22-002081.txt : 20220301
0001415889-22-002081.hdr.sgml : 20220301
20220301200125
ACCESSION NUMBER: 0001415889-22-002081
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220226
FILED AS OF DATE: 20220301
DATE AS OF CHANGE: 20220301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LAMPROPOULOS FRED P
CENTRAL INDEX KEY: 0000901534
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-18592
FILM NUMBER: 22700724
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MERIT MEDICAL SYSTEMS INC
CENTRAL INDEX KEY: 0000856982
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 870447695
STATE OF INCORPORATION: UT
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1600 WEST MERIT PARK WAY
CITY: SOUTH JORDAN
STATE: UT
ZIP: 84095
BUSINESS PHONE: 8012531600
MAIL ADDRESS:
STREET 1: 1600 WEST MERIT PARKWAY
CITY: SOUTH JORDAN
STATE: UT
ZIP: 84095
4
1
form4-03012022_050303.xml
X0306
4
2022-02-26
0000856982
MERIT MEDICAL SYSTEMS INC
MMSI
0000901534
LAMPROPOULOS FRED P
1600 WEST MERIT PARKWAY
SOUTH JORDAN
UT
84095
true
true
false
false
PRESIDENT AND CEO
Common Stock, No Par Value
2022-02-26
4
A
0
17680
0
A
985596
D
Common Stock, No Par Value
2022-02-28
4
F
0
7832
65.03
D
977764
D
Common Stock, No Par Value
96357
I
By 401(k) Plan
Common Stock, No Par Value
3859
I
By spouse
Common Stock, No Par Value
90
I
By spouse as custodian for child
Non-qualified stock options (right to buy)
65.03
2022-02-26
4
A
0
48566
0
A
2023-02-28
2029-02-28
Common Stock
48566
48566
D
Non-qualified stock options (right to buy)
16.05
2017-01-28
2023-01-28
Common Stock
50000
50000
D
Non-qualified stock options (right to buy)
16.05
2017-01-28
2023-01-28
Common Stock
6000
6000
I
See footnote
Non-qualified stock options (right to buy)
28.20
2018-04-14
2024-04-14
Common Stock
200000
200000
D
Non-qualified stock options (right to buy)
28.20
2018-04-14
2024-04-14
Common Stock
6000
6000
I
See footnote
Non-qualified stock options (right to buy)
44.80
2019-03-02
2025-03-02
Common Stock
38002
38002
D
Non-qualified stock options (right to buy)
44.80
2019-03-02
2025-03-02
Common Stock
4000
4000
I
See footnote
Non-qualified stock options (right to buy)
55.73
2020-03-01
2026-03-01
Common Stock
159151
159151
D
Non-qualified stock options (right to buy)
55.73
2020-03-01
2026-03-01
Common Stock
2000
2000
I
See footnote
Non-qualified stock options (right to buy)
37.71
2021-02-26
2027-02-26
Common Stock
100334
100334
D
Non-qualified stock options (right to buy)
56.25
2022-03-19
2028-03-19
Common Stock
58083
58083
D
These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee and Board of Directors that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02/26/2020.
Represents plan holdings as of 02/28/2022.
Becomes exercisable in equal annual installments of 25% commencing 2/28/2023.
Became exercisable in equal annual installments of 20% commencing 1/28/2017.
Original grant of 7,500 options was to become vested and exercisable in equal annual installments of 20% commencing 1/28/2017. Options not vested as of 6/22/2020 have been forfeited.
Becomes exercisable in equal annual installments of 20% commencing 4/14/2018.
Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 4/14/2018. Options not vested as of 6/22/2020 have been forfeited.
Becomes exercisable in equal annual installments of 20% commencing 3/2/2019.
Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 3/2/2019. Options not vested as of 6/22/2020 have been forfeited.
Becomes exercisable in equal annual installments of 20% commencing 3/1/2020.
Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 3/1/2020. Options not vested as of 6/22/2020 have been forfeited.
Becomes exercisable in equal annual installments of 25% commencing 2/26/2021.
Becomes exercisable in equal annual installments of 25% commencing 3/19/2022.
/s/ Brian G. Lloyd, Attorney-in-Fact
2022-03-01